Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	44.71B
Revenue (ttm)	8.34B
Net Income (ttm)	1.83B
Shares Out	6.60B
EPS (ttm)	0.28
PE Ratio	24.52
Forward PE	17.14
Dividend	0.04 (0.55%)
Ex-Dividend Date	Sep 30, 2024

Volume	94,100,473
Average Volume	34,943,493
Open	6.99
Previous Close	6.95
Day's Range	6.76 - 6.99
52-Week Range	6.42 - 8.68
Beta	0.54
RSI	35.74
Earnings Date	Apr 18, 2025

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2023, SHE:002252's revenue was 7.96 billion, an increase of 21.27% compared to the previous year's 6.57 billion. Earnings were 1.78 billion, a decrease of -5.35%.